TABLE 1.
The basic characteristics of the two cohorts of PCa.
| Clinical characteristics | Classification | TCGA (n = 472) | MSKCC (n = 138) |
| Age | 60.87 ± 6.80 | 58.03 ± 6.63 | |
| PSA | 10.86 ± 11.67 | 12.14 ± 44.08 | |
| Gleason score | 6 | 44 (9.32%) | 41 (29.71%) |
| 7 | 237 (50.21%) | 77 (55.80%) | |
| 8 | 57 (12.08%) | 10 (7.25%) | |
| 9 | 131 (27.75%) | 10 (7.25%) | |
| 10 | 3 (0.64%) | 0 (0%) | |
| WHO ISUP | 1 | 44 (9.32%) | 41 (29.71%) |
| 2 | 142 (30.08%) | 53 (38.41%) | |
| 3 | 95 (20.13%) | 24 (17.39%) | |
| 4 | 57 (12.08%) | 10 (7.25%) | |
| 5 | 134 (28.39%) | 10 (7.25%) | |
| T stage | T2a | 12 (2.54%) | 8 (5.80%) |
| T2b | 10 (2.12%) | 48 (34.78%) | |
| T2c | 158 (33.47%) | 29 (21.01%) | |
| T3a | 152 (32.20%) | 29 (21.01%) | |
| T3b | 130 (27.54%) | 13 (9.42%) | |
| T3c | 0 (0.00%) | 4 (2.90%) | |
| T4 | 10 (2.12%) | 7 (5.07%) | |
| Biochemical recurrence | Yes | 87 (18.43%) | 35 (25.36%) |
| No | 385 (81.57%) | 103 (74.64%) |
PCa, prostate cancer; TCGA, The Cancer Genome Atlas; MSKCC, MSK-IMPACT Clinical Sequencing Cohort; PSA, prostate-specific antigen.